Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates

分组1 - Protagonist Therapeutics (PTGX) reported quarterly earnings of $1.98 per share, significantly exceeding the Zacks Consensus Estimate of $0.06 per share, and showing a substantial increase from $0.44 per share a year ago, resulting in an earnings surprise of 3,200% [1] - The company achieved revenues of $170.64 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 202.56%, compared to $60 million in the same quarter last year [2] - Protagonist Therapeutics has outperformed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates two times during the same period [2] 分组2 - The stock has underperformed the market with a loss of about 0.3% since the beginning of the year, while the S&P 500 has gained 4% [3] - The current consensus EPS estimate for the upcoming quarter is $0.58 on revenues of $88.02 million, and for the current fiscal year, it is -$0.64 on revenues of $163.2 million [7] - The Medical - Biomedical and Genetics industry, to which Protagonist Therapeutics belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]